CA2682608A1 - Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome - Google Patents

Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome Download PDF

Info

Publication number
CA2682608A1
CA2682608A1 CA002682608A CA2682608A CA2682608A1 CA 2682608 A1 CA2682608 A1 CA 2682608A1 CA 002682608 A CA002682608 A CA 002682608A CA 2682608 A CA2682608 A CA 2682608A CA 2682608 A1 CA2682608 A1 CA 2682608A1
Authority
CA
Canada
Prior art keywords
ibs
hydroxypyrrolidin
ethyl
phenyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002682608A
Other languages
English (en)
French (fr)
Inventor
Allen Mangel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tioga Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2682608A1 publication Critical patent/CA2682608A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
CA002682608A 2007-03-30 2008-03-07 Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome Abandoned CA2682608A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92084107P 2007-03-30 2007-03-30
US60/920,841 2007-03-30
PCT/US2008/056317 WO2008121496A1 (en) 2007-03-30 2008-03-07 Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome

Publications (1)

Publication Number Publication Date
CA2682608A1 true CA2682608A1 (en) 2008-10-09

Family

ID=39795494

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002682608A Abandoned CA2682608A1 (en) 2007-03-30 2008-03-07 Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome

Country Status (19)

Country Link
US (2) US7960429B2 (cg-RX-API-DMAC10.html)
EP (3) EP2136801B1 (cg-RX-API-DMAC10.html)
JP (2) JP5416085B2 (cg-RX-API-DMAC10.html)
KR (2) KR101208326B1 (cg-RX-API-DMAC10.html)
CN (2) CN101677997B (cg-RX-API-DMAC10.html)
AU (1) AU2008232954A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0809651A2 (cg-RX-API-DMAC10.html)
CA (1) CA2682608A1 (cg-RX-API-DMAC10.html)
CY (1) CY1113317T1 (cg-RX-API-DMAC10.html)
DK (1) DK2136801T3 (cg-RX-API-DMAC10.html)
ES (1) ES2393815T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20120798T1 (cg-RX-API-DMAC10.html)
IL (1) IL201226A0 (cg-RX-API-DMAC10.html)
MX (1) MX2009010409A (cg-RX-API-DMAC10.html)
PL (1) PL2136801T3 (cg-RX-API-DMAC10.html)
PT (1) PT2136801E (cg-RX-API-DMAC10.html)
RU (1) RU2441655C2 (cg-RX-API-DMAC10.html)
SI (1) SI2136801T1 (cg-RX-API-DMAC10.html)
WO (1) WO2008121496A1 (cg-RX-API-DMAC10.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101677997B (zh) * 2007-03-30 2012-05-09 泰奥加制药公司 用于治疗腹泻型和交替型肠易激综合征的κ-阿片剂激动剂
WO2012012410A2 (en) * 2010-07-19 2012-01-26 Dr. Reddy's Laboratories Ltd. Kappa opioid receptor agonists
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
BR112015015258A2 (pt) 2012-12-24 2017-09-26 Neurogastrx Inc métodos para tratar distúrbios do trato gastrintestinal
WO2015200369A1 (en) 2014-06-24 2015-12-30 Neurogastrx, Inc. Prodrugs of metopimazine
JP6410641B2 (ja) 2015-03-04 2018-10-24 ローム株式会社 ワイヤレス送電装置、異物検出方法、充電器
WO2018035046A1 (en) 2016-08-15 2018-02-22 President And Fellows Of Harvard College Treating infections using idsd from proteus mirabilis
EP3558300B1 (en) 2016-12-21 2021-11-24 Tioga Pharmaceuticals, Inc. Solid pharmaceutical formulations of asimadoline
WO2019122361A1 (en) 2017-12-22 2019-06-27 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Asimadoline for use in treating pulmonary diseases, vascular diseases, and sepsis
CN118512451A (zh) 2018-07-23 2024-08-20 特雷维治疗股份有限公司 慢性咳嗽、呼吸急促和呼吸困难的治疗
IL294601A (en) 2020-01-10 2022-09-01 Trevi Therapeutics Inc Methods of administration of nalbuphine
EP4121083A4 (en) * 2020-03-18 2023-11-29 Cara Therapeutics, Inc. OLIGOSACCHARIDE FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
EP3932390A1 (en) 2020-07-02 2022-01-05 Dr. August Wolff GmbH & Co. KG Arzneimittel Topical gel formulation containing asimadoline
JP7464744B2 (ja) * 2020-10-20 2024-04-09 セトラスホールディングス株式会社 診療支援装置、診療支援方法、診療支援プログラム及び診療支援システム
WO2022155332A1 (en) * 2021-01-13 2022-07-21 Blue Therapeutics, Inc. Methods of treating irritable bowel syndrome

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4192883A (en) * 1976-04-09 1980-03-11 Pierre Fabre, S.A. Amides of pyrrolidinoethylamine which can be used in lung therapy
FR2421891A1 (fr) 1977-10-17 1979-11-02 Fabre Sa Pierre Obtention industrielle d'amides de la pyrrolidine ethyl amine
US4663343A (en) * 1985-07-19 1987-05-05 Warner-Lambert Company Substituted naphthalenyloxy-1,2-diaminocyclohexyl amide compounds
US4889860A (en) * 1985-09-23 1989-12-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4760069A (en) * 1985-09-23 1988-07-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
GB8601796D0 (en) * 1986-01-24 1986-02-26 Zambeletti Spa L Compounds
EP0330467A1 (en) 1988-02-23 1989-08-30 Glaxo Group Limited Heterocyclic compounds
DE3935371A1 (de) 1988-12-23 1990-07-05 Merck Patent Gmbh Stickstoffhaltige ringverbindungen
US5232978A (en) * 1988-12-23 1993-08-03 Merck Patent Gesellschaft Mit Beschrankter Haftung 1-(2-arylethyl)-pyrrolidines
DE4034785A1 (de) 1990-11-02 1992-05-07 Merck Patent Gmbh 1-(2-arylethyl)-pyrrolidine
US5389686A (en) * 1989-02-20 1995-02-14 Jouveinal Sa Analgesic properties of fedotozine
DE3916663A1 (de) * 1989-05-23 1990-11-29 Bayer Ag Substituierte (chinolin-2-yl-methoxy)phenyl-acyl-sulfonamide und -cyanamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
CA2021817C (en) * 1989-07-24 2000-09-26 William J. Mork Upholstered article of furniture with interchangeable seating module
EP0501997B1 (en) 1989-11-24 1997-01-29 Smithkline Beecham S.p.A. N-acyl-substituted azacyclic compounds, processes for their preparation, and their use as pharmaceuticals
GB8926560D0 (en) 1989-11-24 1990-01-17 Zambeletti Spa L Pharmaceuticals
US5300687A (en) 1991-07-18 1994-04-05 Ortho Pharmaceutical Corporation Trifluoromethylbenzylphosphonates useful in treating osteoporosis
DE4215213A1 (de) * 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide
DE4425071C2 (de) * 1994-07-15 1996-08-29 Degussa Verfahren zur Herstellung optisch aktiver Pyrrolidine mit hoher Enantiomerenreinheit
DE19523502A1 (de) 1995-06-28 1997-01-02 Merck Patent Gmbh Kappa-Opiatagonisten für entzündliche Darmerkrankungen
DE19531464A1 (de) 1995-08-26 1997-02-27 Merck Patent Gmbh N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid
DE69833000T2 (de) * 1997-09-26 2006-09-07 Noven Pharmaceuticals, Inc., Miami Bio-klebemittelzusammensetzungen
US20010051181A1 (en) * 1997-12-22 2001-12-13 Van Osdol William W. Novel formulations for the transdermal administration of asimadoline
DE19827633A1 (de) 1998-04-20 1999-10-21 Merck Patent Gmbh Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid
EP1093370B1 (en) * 1998-06-30 2006-02-22 Takeda Pharmaceutical Company Limited Pharmaceutical composition for the treatment of diabetes
JP2000080047A (ja) 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
DE19849650A1 (de) * 1998-10-29 2000-05-04 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung des Irritable Bowel Syndroms (IBS)
DE60018225T2 (de) * 1999-03-01 2005-12-29 Pfizer Products Inc., Groton Oxamsäuren mit einer Cyanogruppe als Liganden für den Thyroidrezeptor
US20020025948A1 (en) * 2000-06-23 2002-02-28 Banks Bernard Joseph 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
GB0015562D0 (en) 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
US6262062B1 (en) 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6846831B2 (en) * 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US6569449B1 (en) * 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
DE10116978A1 (de) 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
AU2002364517A1 (en) 2001-11-30 2003-06-17 Sepracor Inc. Tramadol analogs and uses thereof
US20050176746A1 (en) * 2002-05-17 2005-08-11 Frank Weber Use of compounds that are effective as selective opiate receptor modulators
MXPA05002983A (es) * 2002-09-18 2005-06-22 Univ Missouri Analogos de opiato selectivos del receptor opioide d.
DE10259245A1 (de) 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
JP2006522817A (ja) 2003-04-08 2006-10-05 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 過敏性腸症候群を処置するための末梢オピオイドアンタゴニスト、特にメチルナルトレキソンの使用
PL2368554T3 (pl) 2003-04-08 2015-05-29 Progenics Pharm Inc Preparaty farmaceutyczne zawierające metylonaltrekson
PL1644021T3 (pl) * 2003-06-13 2013-01-31 Ironwood Pharmaceuticals Inc Sposoby i kompozycje do leczenia zaburzeń żołądkowo-jelitowych
JP2007509865A (ja) * 2003-10-30 2007-04-19 ティオガ ファーマシュウティカルズ，インコーポレイテッド 神経障害の治療における選択的オピエート受容体調節物質の使用
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
CN101677997B (zh) 2007-03-30 2012-05-09 泰奥加制药公司 用于治疗腹泻型和交替型肠易激综合征的κ-阿片剂激动剂

Also Published As

Publication number Publication date
KR20120058614A (ko) 2012-06-07
EP2561870A1 (en) 2013-02-27
RU2441655C2 (ru) 2012-02-10
HK1139860A1 (en) 2010-09-30
SI2136801T1 (sl) 2013-01-31
AU2008232954A1 (en) 2008-10-09
RU2009140042A (ru) 2011-05-10
EP2136801A4 (en) 2010-05-26
EP2136801B1 (en) 2012-08-29
CN102641265A (zh) 2012-08-22
EP2136801A1 (en) 2009-12-30
IL201226A0 (en) 2010-05-31
BRPI0809651A2 (pt) 2014-10-07
US20080242720A1 (en) 2008-10-02
JP2013173790A (ja) 2013-09-05
CY1113317T1 (el) 2016-04-13
US8877800B2 (en) 2014-11-04
PL2136801T3 (pl) 2013-01-31
KR101263225B1 (ko) 2013-05-13
AU2008232954A2 (en) 2011-12-01
JP5416085B2 (ja) 2014-02-12
KR101208326B1 (ko) 2012-12-05
EP2636407A2 (en) 2013-09-11
US20110046174A1 (en) 2011-02-24
DK2136801T3 (da) 2012-12-17
CN101677997A (zh) 2010-03-24
EP2636407A3 (en) 2013-11-06
ES2393815T3 (es) 2012-12-28
MX2009010409A (es) 2010-03-29
KR20100016004A (ko) 2010-02-12
CN101677997B (zh) 2012-05-09
PT2136801E (pt) 2012-12-06
US7960429B2 (en) 2011-06-14
JP2010523492A (ja) 2010-07-15
WO2008121496A1 (en) 2008-10-09
HRP20120798T1 (hr) 2012-11-30

Similar Documents

Publication Publication Date Title
US7960429B2 (en) Kappa-opiate agonists for the treatment of diarrhea-predominant irritable bowel syndrome
US11285139B2 (en) Treatment of CNS conditions
Sandner‐Kiesling et al. Long‐term efficacy and safety of combined prolonged‐release oxycodone and naloxone in the management of non‐cancer chronic pain
RU2437661C2 (ru) Милнаципран в качестве средства для продолжительного лечения синдрома фибромиалгии
KR20130106431A (ko) 파킨슨병의 치료에 있어서 오피오이드 효능제와 오피오이드 길항제의 조합물
US20110070319A1 (en) Bifeprunox doses for treating schizophrenia
SK10552002A3 (sk) Kombinácia a jej použitie
US20130310412A1 (en) Combinations of an Opioid/TLR4 Antagonist and a Direct-Acting Alpha-2 Adrenergic Agonist for Use in the Treatment of Pain
HK1139860B (en) Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome
CA2675243A1 (en) Milnacipran for the treatment of fatigue associated with fibromyalgia syndrome
US8592466B2 (en) Methods for treating conditions caused by higher-than-normal dopaminergic activity in basal ganglia
MX2008004197A (en) Milnacipran for the long-term treatment of fibromyalgia syndrome
TW201103546A (en) New use of 5H-dibenz/b,f/azepine-5-carboxamide derivatives

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20150309